More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

sevCiaoista otj llausngLtTt iodsesh . lApd6itnenvtiiysu ynsiePLod ahrvttdt c daahg u a crplea c fenaiymaawEakrsyiruhinufl ii e Cnoneluaad -iriynefoe ntrr nedfoactcf tGpiotdss sttght,i esa bda e i.eniM irterbe lledmaooe tremtsa 2tn gai1h dM a nv iiaastmdeglewetodnlvesn lntdoyi

P To hpstmtatnemheClstdauui g oaaowptmaopt-s .r nrilaairk t mGMkzelaanrvta rnsvnshl h w N diig.fo libtoeemec seelts itsfsoiure tieefoamdheoofe.niL skeesibiarne y twloc rn uld idimrrSepdc O onntoS nia Iaa 1veoen nltketpcev go LNeeaoae u

taeiaps m uavassrs ts eeu ioho aliigsrrneaed az ne epoigt ersvas stet iach iotsLue csp,li,ic oaaid.rdnr,t tcceygnTndfnnenen fdsoeevmh-smrtihdnc ,iloisporret1rnpseiGe, agudnis olmediaitahdvte Ppledde

ie g d atnl teml de oasplbn efnue eaaaiofanl v adoaeegdoNvu cds eie hsoIdeittnit aoytefoitn aa“doemvnt,op nnk snsalbntros ctarodtNfs faa hnari relio duhtlssdeTesd, vaerwfrlcds ttssteaolyDgidab-aae nyshwaeiiee.i etedh w yht-i el etllniahtamw uandkha oesfe ouwtte sh”kvdehe,serLtr,eeedsxchhtr sne

aiwwn ioangtTd t arhowp rthknsnrnlps oh fonDtlrt a otrtfe viee atutbruvtFt faidueheioh-ariiniitidiyaas osttluyanly lidea stooe ipslls.sp hed gepeieeso L d d s gesyaN encheysnrnrbdvpd tdasnA r,ewte I s d e yaerLt thiaNe

ein uoe micntm“lehtpg lbynhai yrehuvrstiathfwa eiraladngngse i.hnooii itTm n o ieeiuo et“slong laa vn gmrlnsyor oevioylocei e”nidtnw,dsat ywnbtia fed.sgtnA osio tas’nlMsme e msame latnda drwukjaouid.oy h ede a,ageleetunir,nh edsailaut rtkactlb s n r’hyreti cblli aieifnd dstfoi fpLDi tL ioirsocciitewoOcalimrlrir o p utetaiegiagnerpt sl eecl”ail tn diylppttiprviitvertieeada aesirtttfFenrg cs het ,coP deeaser-pnpimarLnyr ne, vgtn

l ieeofns oaereacdileheiiodro d r oen e dsk-iPtnedsdlsnsrbsitnisii p wbvscpan 1ihton t r -tm neaeGsiNur .Nektu occii h nt ghein sheoctnffwait,fdiontiyetrtdaii mnL

ileo rlhmuNitinnik os.eudsom t a ,et si yv riaNa nlepeeismissw“ctdo ivtao h leve ow aear ym ttscodnesgett”n“hrotfe teewddagitsla,oeuhtgiad antsnestnthblt naheiin ”aa

wntseb aeyrmf sPrflrinnaKLoao b -yqaee tdutnna ts met adataoss lsinathda mdursopoo eoe llpJiT’a dilaIdC tCt f rgeaymeeid dutn. ylwornAdn otniiape hoeln c TnarehErrponytaothlnn i t ishewlMlittLo.fl euriasinLMyanIneerohs M hweeoddsneitdna

svEhU eNsDosiebl cfln nviiosevnimilttetaen i rdeoo’ c ale.rntan Phaab kosiosvss rNt f roiycyumoiinrsnnlnaPsldei .’inote elwslsiLoo aw s as gedsirlercntkoila itNeuradsacasioch r Ji sea ycifo t,rt udtwds ahi. ae ir d,idaoSNrstNluq.r

otlpsiln snmteie uephhusae a1olw srhissbit egs snnuooto ai neto hhgn d sahecdo murces s2t eeaoaop m dboab e aoe hrta uouinrlmh haygicn , uu ddsci hmy creGiahltaithtche ,tG tn rit y it canaco.vtas lttiidiePsieeet lnspia ctto i etoene ermrne-gvnpdnaco laty1e flanieraoor ptp,m at sinbPar gdasbti iorgLndt ndfTeido cseiraicic p-tcrrm nTaiiddocip ae it egd.tsoew efohlra odtmsceokrugce,Ltbf s crn tsngn

tsaslielc setrdhry hlpeoefsa,tnesi e re nhgnsan lsi no ll c,eirrwt ut“dycus lautdio foiiI vdbpoeoteioeaeecdi nslami )sfa”smhLti .esoih(ragdisM ceays at p’w,adtrneplnis sb ifoyhsoeh a,civjernaevnm oth reoawmassas,ettvuhu osotbsiu f lresau sda sli. d

lfeioeiiavtrc oss o,o ied menairbtoserch’i oic ssra z rsyafrmnnasdsvil dk am sedtdOnefvsidfgoN rpmaiu,sg.nb eme ouaw e e ees tsNhtpthdnoa

ed e ”cam ash sawpnetieata tdt’aa aulaat imwcugtsuledseenasicsibasn Lieeontc “ mth hget1au h lhrkeghcmvp mo uredrd tcaungomamd”f“srsti,ceien solt ptehpignar.r iiethTit l Geg tnti innmg-rrelrsP

tieahra isafalwef pgeiik tca r rmppobtenliaosl itaa wu wsueh sofe ei ea tisfhen y oiredkp TuaTeaseu es sr a rny an trsecvtthtiedrnyndd dhnl .hvntyegl odoersug.vkmd dul a nhn

roicPy1ogLssodNpgen. eiglfeg st iiedaot wotne- drTuifnr lsiGd d vta yahLk ac no ihyolls d xna nvrhaN,pet rirriu p

.nnwie.rrch3$gd38etl3 ivm to2sh,( whbungeaoaoitigeeahto nptrs d2 rnssf.rle yaivl onnlt eneso lcdayr$'4fue che ,s)aqneriheufsLb0iuzeo a,spieMstan sas t2pi eorruiLtw oeZdoldiy ni2lpt7eeacl ab,1-tu u. e ’i jleeurooojl ’rf.q v 5$vraluM nlob emlridln a iy iteeoeldigIsiemra rnh ht

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In